bio-america-2016_posters-accepted-abstracts

10 / 16

Page 62
Notes:
conferenceseries.com
Volume 6, Issue 8 (Suppl) J Biotechnol Biomater
ISSN: 2155-952X JBTBM, an open access journal Bio America 2016
November 28-30, 2016
November 28-30, 2016 San Francisco, USA
13th Biotechnology Congress
Jee-Yeon Ryu et al., J Biotechnol Biomater 2016, 6:8(Suppl)
Nanoliposome particle possessing protein based CRISPR/Cas9 system for the therapeutic applications
Jee-Yeon Ryu, Eun Yi Cho and Tae-Jong Yoon
Ajou University, South Korea
Gene editing (CRISPR/Cas9) technology has been spotlighted as a superior therapeutic tool that is capable of treating the
fundamental causes of disease induced by genetic abnormalities, which to date have been considered as incurable diseases.
Thus many researchers have focusing establishment of gene editing moiety delivering, because efficient and safe delivery in the body
remains one of the major challenges of biomedical and nano-pharmaceutical research. A plasmid based CRISPR/Cas9 system has
shown several critical limitations such as off-targeting, integration of DNA segment and toxicity of transfection agent. To overcome
these problem, protein based CRISPR/Cas9 system was recently co-opted to the therapeutic or gene editing method. However, the
protein system has still remained the stability problems, especially in in vivo system as like degradation by enzymatic reaction or
low efficiency. Herein, we elucidate novel method for the delivery system of protein based CRISPR/Cas9 with high efficient and bio-
compatibility. The CRISPR/Cas9 complex was successfully encapsulated into the nanometer sized liposome (nanoliposome), which
was composited with bioapplicable phospholipid chemicals throughmetal coordination reaction. After chemical surface modification,
the nanoliposome with gene editing materials was shown long term solution stability without agglomeration and penetrated well into
the cell cytosol. We suggest optimization of preparation for the nanoliposomal protein based CRISPR/Cas9 system as a platform
particle to the therapeutic application. As a proof of concept, the nanoliposome with CRISPR/Cas9 system was exploited to apply
for the type-2 diabetes therapy and exhibited effectiveness of glucose control without off-targeting, acute toxicity and degradation.
More importantly, our particle platform systemwas shown higher regulation effect than a clinical used chemical drug without various
adverse reactions effect including renal disorder or allergic reaction.
Biography
Jee-Yeon Ryu is currently a PhD candidate at Ajou University College of Pharmacy. She is studying synthesis of nanomaterials aimed at biological applications.